tag adjuvant 
The Pharma Data
JANUARY 31, 2021
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. The study found that Clover’s adjuvanted S-Trimer COVID-19 vaccine candidates were well tolerated and safe. CHENGDU, China , Feb.
The Pharma Data
DECEMBER 3, 2020
The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 31, 2021
Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.
pharmaphorum
OCTOBER 29, 2021
Merck is the obvious partner for that ambition as Keytruda is in the ascendency among checkpoint inhibitors for TNBC, having also recently also picked up an FDA approval pre-surgery alongside chemotherapy in the neoadjuvant setting, as well as in the post-surgery (adjuvant) setting as a monotherapy, to prevent tumours from recurring.
XTalks
AUGUST 17, 2020
Using chemistries, we can then tag on different T cell epitopes – [this] is in contrast to the Immuno-STAT where each peptide that is bound to the HLA is made as a fusion protein so it needs its own separate cell line,” Dr. Later this year, Cue Biopharma intends to start a combination study with Merck’s pembrolizumab (a PD-L1 inhibitor).
Expert insights. Personalized for you.
52 
Let's personalize your content